InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.725 0.015 (2.11%)+
Announcement
Release
3 Jul 2026 9:29AM
Price at Release
$0.710
Full Release
download
Summary
Starpharma Holdings Limited has announced a key milestone in its collaboration with Radiopharm Theranostics, resulting in a AUD $0.5 million option fee to Starpharma. This milestone indicates a significant advancement in their program, allowing Radiopharm to enter an option period where they may choose to license Starpharma's DEP® dendrimer technology. If Radiopharm exercises this option, Starpharma could potentially receive up to AUD $91 million through various payments and royalties. This achievement further signifies the commercial viability and external validation of Starpharma's DEP® platform, particularly in the field of radiopharmaceutical development. The collaboration involves developing and manufacturing a dendrimer-drug conjugate for a radiopharmaceutical asset under development by Radiopharm. Starpharma's CEO, Cheryl Maley, emphasized the productive nature of this partnership and its impact on the global oncology sector.
Key Points
  • Starpharma achieves a milestone triggering a AUD $0.5 million option fee.
  • Collaboration with Radiopharm Theranostics moves to an option period.
  • Potential for Starpharma to earn up to AUD $91 million if option is exercised.
  • Milestone marks further validation of Starpharma's DEP® platform.
  • DEP® technology applied to develop a dendrimer-drug conjugate.
  • Starpharma's CEO highlights the significance of the collaboration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.